AtriCure falls under the Medical - Products industry. Currently, this industry has 83 stocks and is ranked #66. Since the beginning of the year, the industry has moved +9.9%. AnaptysBio ...

San Diego-based AnaptysBio Inc. (NASDAQ ... and a 10% royalty on net sales of the product. Imsidolimab has already cleared two phase 3 clinical trials in which it proved to be safe and effective ...

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company ...

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB ... “We are excited to add imsidolimab to Vanda’s product portfolio for rare orphan disorders, as well as explore the potential of this ...

AnaptysBio’s Phase IIb trial of its rheumatoid ... supported by objective translational data and surpass our target product profile in the $20bn US RA market." Faga added that in Q2 2025 ...

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in ...

Discovering AnaptysBio: A Closer Look AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in ...